December 6, 2011

In a private, closed door meeting, Stephen J. Petti, CEO of Hibernaid, Inc. discussed Hibernaid’s pharmaceutically-induced hypothermia program for the treatment of post-cardiac arrest, which may also have potential in treating stroke, traumatic brain injury, spinal cord injury and other medical conditions where survival and neurological function are at risk.

Guest Presenter:

George Damis Yancopoulos M.D., Ph.D.
Chief Scientific Officer & Founding Scientist
Regeneron Pharmaceuticals

Presenting Companies:

Interleukin Genetics – Lewis Bender, Chief Executive Officer

Egenix – Jedd Levine, Chief Medical Officer

Cytosorbents Inc. – Phillip Chan, Chief Executive Officer & President (update)

Click here for full Program details.